Key Points
- Tim Kutzkey bought 12,470 shares of Surrozen on January 13 at $19.80 per share for $246,906, bringing his direct stake to 996,502 shares (a 1.27% increase) valued at about $19.73 million.
- That trade is part of a recent insider buying spree—multiple purchases from November through mid-January total roughly $5.34 million in acquisitions, indicating increased insider accumulation.
- Surrozen shares trade around $20 (52-week range $5.90–$24.94) with a market cap of $171.4M, negative EPS, and a consensus analyst rating of “Moderate Buy” with a $32 price target.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Group Gp Lp Column III acquired 5,523 shares of the stock in a transaction that occurred on Wednesday, January 14th. The stock was purchased at an average price of $19.99 per share, for a total transaction of $110,404.77. Following the completion of the transaction, the insider owned 999,429 shares in the company, valued at $19,978,585.71. The trade was a 0.56% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Group Gp Lp Column III also recently made the following trade(s):
- On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The stock was purchased at an average price of $19.80 per share, with a total value of $246,906.00.
- On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The shares were purchased at an average price of $19.89 per share, for a total transaction of $300,339.00.
- On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The shares were purchased at an average cost of $19.54 per share, with a total value of $603,473.36.
- On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $91,365.10.
- On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were acquired at an average price of $12.65 per share, for a total transaction of $3,990,531.05.
Surrozen Stock Performance
Shares of SRZN stock opened at $20.00 on Friday. The stock has a 50 day simple moving average of $18.54 and a 200-day simple moving average of $13.84. The company has a market cap of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94.
Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on SRZN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a report on Wednesday, October 8th. Lifesci Capital raised Surrozen to a "strong-buy" rating in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded Surrozen to a "sell" rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $32.00.
Read Our Latest Research Report on Surrozen
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Woodline Partners LP acquired a new stake in shares of Surrozen during the third quarter valued at about $621,000. Millennium Management LLC purchased a new position in Surrozen in the third quarter valued at about $1,414,000. Citadel Advisors LLC grew its stake in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock valued at $179,000 after purchasing an additional 3,424 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Surrozen during the 3rd quarter worth approximately $889,000. Finally, Acuta Capital Partners LLC raised its position in shares of Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company's stock valued at $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company's stock.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
